Related Experiment Video

Updated: Mar 11, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K

Regulation of protein phosphatase 2A (PP2A) tumor suppressor function by PME-1

Amanpreet Kaur1,2, Jukka Westermarck1,2

  • 1Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, PO Box 123, Tykistökatu 6, 20520 Turku, Finland.

Biochemical Society Transactions
|December 4, 2016
PubMed

Insights

Protein phosphatase methylesterase-1 (PME-1) negatively regulates tumor suppressor PP2A. PME-1 promotes cancer pathways and is linked to glioma progression and treatment resistance, suggesting clinical relevance.

Area of Science:

  • Cellular Biology
  • Molecular Oncology
  • Biochemistry

Background:

  • Protein phosphatase 2A (PP2A) is crucial for cellular signaling homeostasis and tumor suppression.
  • Protein phosphatase methylesterase-1 (PME-1) is a key negative regulator of PP2A activity.
  • Dysregulation of PP2A and PME-1 is implicated in various cellular processes.

Purpose of the Study:

  • To review the complex regulatory mechanisms of PP2A by PME-1.
  • To highlight the emerging role of PME-1 in promoting oncogenic signaling pathways.
  • To discuss the clinical relevance of PME-1 in cancer, particularly human glioma.

Main Methods:

  • Literature review of existing studies on PME-1 and PP2A.
  • Analysis of recent research linking PME-1 to MAPK/ERK and AKT pathway activation.
  • Examination of data correlating PME-1 expression with glioma progression and therapeutic resistance.

Main Results:

  • PME-1 negatively impacts PP2A function through intricate mechanisms.
  • PME-1 actively promotes oncogenic MAPK/ERK and AKT signaling in diverse cancer types.
  • Elevated PME-1 expression in human glioma correlates with advanced tumor stage and resistance to kinase inhibitors.

Conclusions:

  • PME-1 plays a significant role in promoting cancer development and progression.
  • PME-1's association with oncogenic pathways and clinical resistance highlights its potential as a therapeutic target.
  • Further investigation into PME-1's function is warranted for its clinical application in oncology.
Keywords:
LCMT-1PTPAcolorectal cancerendometrial cancergliomaneuroendocrine prostate cancer

More Related Videos

A Mass Spectrometry-Based Approach to Identify Phosphoprotein Phosphatases and their Interactors10:17

A Mass Spectrometry-Based Approach to Identify Phosphoprotein Phosphatases and their Interactors

Published on: April 29, 2022

2.9K
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

849

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.7K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.4K